Tai Patricia, Yu Edward, Assouline Avi, Lian Ji Dong, Kurian Joseph, Krzisch Claude
Department of Radiation Oncology, Allan Blair Cancer Center, Regina, Canada.
J Drugs Dermatol. 2010 Feb;9(2):105-10.
A case series of Merkel cell carcinoma (MCC) is reported here and illustrates some of the current controversies in clinical management of this disease. From 1988-2007, 145 cases (74 men and 71 women) were analyzed. These were combined with other cases in the literature, hence the total number of patients was 433. Nodal metastases occurred clinically at presentation in 9/105 (9%) patients with primary tumor size <1 cm. The rate of nodal metastases is too high to obviate sentinel node biopsies even for these small tumors. For the 87 patients with intermediate tumor size (>1 - <2 cm), nodal metastases occurred clinically in 11 of 87 patients (13%) at presentation and 23 of 87 patients (26%) during follow-up. Distant metastases occurred in 20 of 87 patients (23%) only at follow-up. The risks of nodal and distant failures for tumors of intermediate sizes were sufficient to be classified as high-risk for clinical study purposes.
本文报告了一组默克尔细胞癌(MCC)病例,并阐述了该疾病临床管理中当前存在的一些争议。对1988年至2007年间的145例病例(74例男性和71例女性)进行了分析。这些病例与文献中的其他病例相结合,因此患者总数为433例。原发性肿瘤大小<1 cm的105例患者中,有9例(9%)在就诊时出现临床淋巴结转移。即使对于这些小肿瘤,淋巴结转移率也过高,无法避免前哨淋巴结活检。对于87例中等肿瘤大小(>1 - <2 cm)的患者,87例中有11例(13%)在就诊时出现临床淋巴结转移,87例中有23例(26%)在随访期间出现淋巴结转移。仅在随访期间,87例患者中有20例(23%)出现远处转移。中等大小肿瘤发生淋巴结和远处转移的风险足以在临床研究中被归类为高风险。